Startups
Kymab, a Sanofi company, is a clinical-stage global biopharmaceutical company focused on the discovery and development of fully human monoclonal antibody drugs using its proprietary antibody platform which contains a full diversity of human antibodies, making it the most comprehensive antibody development platform available.
Kymab’s platform has been designed to maximise the diversity of human antibodies produced in response to immunisation with antigens. Selecting from a broad diversity of fully human antibodies assures the highest probability of finding drug candidates with best-in-class characteristics quickly and efficiently.
Kymab’s platform has been designed to maximise the diversity of human antibodies produced in response to immunisation with antigens. Selecting from a broad diversity of fully human antibodies assures the highest probability of finding drug candidates with best-in-class characteristics quickly and efficiently.
Overview
Location
United Kingdom, England, Cambridge
Employees
51-200
Total raised
$239M
Founded date
2010
Funding Rounds 4
| Date | Series | Amount | Investors |
| Sign up to see | Sign up to see | Sign up to see | Sign up to see |
| Nov 24, 2016 | Series C round | $100M | |
| May 6, 2015 | Series B round | $90M | |
| May 16, 2014 | Series B round | $40M |
Mentions in press and media 22
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Jun 24, 2020 | KYMAB WINS SUPREME COURT CASE AGAINST REGENERON | KYMAB WINS SUPREME COURT CASE AGAINST REGENERON Landmark UK Supreme Court Decision Invalidates Regeneron Patent Claims Cambridge, UK; 24 June, 2020: Kymab, a clinical-stage biopharmaceutical company developing fully human monoclonal antibod... |
| Jun 3, 2020 | A low-profile biotech bests Regeneron in high-profile patent suit | For nearly a decade now, the low-profile Cambridge biotech Kymab has been battling in US, UK, Japanese and Australian courts with the biotech behemoth Regeneron. Regeneron has turned itself into a $70 billion company off of... |
| Jun 24, 2019 | Kymab and LifeArc enter strategic partnership to discover new medicines using Kymab’s IntelliSelect® technologies | Cambridge, UK – June 24, 2019: Kymab, a clinical-stage biopharmaceutical company developing antibody-based therapeutics, today announced a strategic partnership agreement with LifeArc, a leading UK medical research charity. The agreement wi... |
| Jul 30, 2018 | Redhill spikes — briefly — on positive Crohn's data; Daiichi inks global licensing deal with Glycotope | → Shares of Israel’s Redhill BioPharma $RDHL spiked Monday morning — then quickly began to slide back — after the biotech laid out data demonstrating how their drug for Crohn’s disease edged out the placebo arm in their first ... |
| Jan 10, 2017 | Kymab Receives $9m Grant from the Bill & Melinda Gates Foundation | Kymab Group Limited, a Cambridge, UK-based monoclonal antibody biopharmaceutical group, received a $9m grant. The Gates Foundation, which has also invested $30m in Kymab’s Series B and Series C financing, will provide the research and devel... |
| Jan 9, 2017 | Kymab receives $9m grant from the Bill & Melinda Gates Foundation | Kymab Group Limited, a leading monoclonal antibody biopharmaceutical group, announced today that it has received a $9m grant from the Bill & Melinda Gates Foundation to accelerate the development of novel vaccines and therapeutics for i... |
| Jan 9, 2017 | Kymab receives $9m grant from the Bill & Melinda Gates Foundation | Kymab receives $9m grant from the Bill & Melinda Gates Foundation 09-01-2017 Kymab Group Limited, a leading monoclonal antibody biopharmaceutical group, announced today that it has received a $9m grant from the Bill & Melinda Gates ... |
| Nov 28, 2016 | Kymab raises $100M to take antibodies into the clinic | Kymab has raised $100 million (€94 million) to fund the advance of its lead candidates into the clinic. The Series C round, which attracted new Chinese investors, brings the total raised by the early-stage British antibody specialist up to ... |
| Nov 28, 2016 | Term Sheet — Monday, November 28 | ET CETERA Happy Cyber Monday, the only time we still use the term “cyber” to describe anything other than cybersecurity. Speaking of that, hackers are holding San Francisco’s public transit system’s data hostage. Paid Content Securing the e... |
Show more
Reviews 0
FAQ about Kymab Ltd
When was Kymab Ltd founded?
Kymab Ltd was founded in 2010.
How much funding has Kymab Ltd raised?
Kymab Ltd has raised $239M in total across 4 funding rounds.
What funding rounds has Kymab Ltd raised?
Parsers VC lists 4 funding rounds of Kymab Ltd, among them a Series C round of $100M on Nov 24, 2016, a Series B round of $90M on May 6, 2015 and a Series B round of $40M on May 16, 2014.
What has the press written about Kymab Ltd?
Parsers VC has collected 22 articles mentioning Kymab Ltd, among them “KYMAB WINS SUPREME COURT CASE AGAINST REGENERON” (Jun 24, 2020) and “A low-profile biotech bests Regeneron in high-profile patent suit” (Jun 3, 2020).
Is Kymab Ltd still active?
Yes, Kymab Ltd is active; its latest activity on Parsers VC dates from Jan 11, 2021.